Let's Win Pancreatic Cancer 💜

Let’s Win is your guide to hope and action.

Our mission is to guide pancreatic cancer patients with vital information for better outcomes. 💜

[Let's Win Pancreatic Cancer 💜 @letswinpc]

Pancreatic cancer is most often caught late. On the latest PancChat, Dr. Ray Wadlow breaks down who should be screened, what genetic mutations to know about, and how the @PrecedeStudy is working to change early detection at a global scale.

Listen: https://t.co/NTlzgBWpWe

[Giovanni Marchegiani @Gio_Marchegiani]

👏 We are all here, in this standing ovation. We are all there, in that Kaplan–Meier curve.

🫶 The hopes of a community. The legacy of those who came before us, and the responsibility entrusted to those who will follow.

Time will tell. But today, we stand here together 💜

[Let's Win Pancreatic Cancer 💜 @letswinpc]

And we have @drallysonocean chatting with @katiecouric about daraxonrasib live on Katie's Substack https://t.co/r6rJ6yhNWd cc @RevMedicines

[Let's Win Pancreatic Cancer 💜 @letswinpc]

El Dr. Jeffrey Crawford, investigador principal, informa sobre los resultados positivos de un ensayo clínico sobre la caquexia en el que se ha probado un nuevo medicamento de inmunoterapia para tratar esta afección. https://t.co/ZraMduIMjP

[Let's Win Pancreatic Cancer 💜 @letswinpc]

Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you. https://t.co/cUA7KU8msU

[Let's Win Pancreatic Cancer 💜 @letswinpc]

@mikecane @starstrickenSF So do we, Mike. So do we.💜🫂

[Sarafina El-Badry Nance, PhD @starstrickenSF]

This standing ovation totally brought me to tears.

On Thursday, my dad (stage 4 pancreatic cancer) started a Revolution Medicine trial building upon these results — RMC 5127, which uses the drug celebrated here, Daraxonrasib, with another drug targeting his specific KRAS mutation, G12V.

He’s nearly 2 years into his fight with pancreatic cancer and we have personally felt the impact of this watershed moment. It is a lifeline.

To the incredible, stalwart, brilliant researchers and folks bringing these discoveries to life - thank you. Thank you thank you thank you.

[Let's Win Pancreatic Cancer 💜 @letswinpc]

👇👇👇👇👇

[Thor Halfdanarson @OncoThor]

Twice today already at ASCO I have heard presenters say “patients failed treatment”.

Can we please, please stop that?

Treatments fail patients, not the other way around…

[Rachel Riechelmann @RachelRiechelm2]

@OncoThor @pashtoonkasi Also: patients do not have RAS, BRAF etc mutations. Tumors do

Patients don’t progress. Tumors do.

[Let's Win Pancreatic Cancer 💜 @letswinpc]

Marla Schreffler had a feeling something was wrong, even after she got her diabetes diagnosis. Further tests confirmed that she had pancreatic cancer. https://t.co/Gwdk2m4lGP

[Allison Fitzgerald, MD, PhD @allisonoconn]

Daraxobrasib isn’t the only exciting pancreatic cancer data coming out today! Here’s some inspiring data about a TCR T cell that targets a specific p53 mutation, and it seems to be working well in the subset of patients with pancreatic cancer! That’s a pretty good spider plot!

[Wungki Park, MD MS @CentralParkWMD]

GRIT = GI Innovative RAS Therapeutics.

Exciting to see leaders (@EileenMOReilly @debschrag @DrVickersMSK Jeff Drebin @MHLars ) across pancreatic cancer and oncology come together as we enter a new chapter of RAS-directed therapies. 💜

Reminiscing our time in the last 4 years and all the thrills we had seeing their tumor marker and CT improving dramatically in our first patients.

From KRAS inhibition to immune modulation and more meaningful combinations, the future is being built through collaboration, innovation, and translation.

#KRAS #RAS #PancreaticCancer #GRIT #ASCO26 @ASCO
@MSK_DeptOfMed @MSKCancerCenter @NatPancFdn @PanCAN @letswinpc @Pankind_Aus @KRASKickers @OncBrothers

[Neil Stone @DrNeilStone]

I've never been at a medical conference where the results have been greeted with a standing ovation

Tremendous breakthrough in pancreatic cancer treatment

Through science

Hard work, rigorous research, clinical trials.

Science

Not the quack pseudoscience of social media

[Dr. Allyson Ocean @drallysonocean]

Standing ovations are rare in oncology.

In pancreatic cancer, they are nearly unheard of.

The applause honored more than a trial—it reflected decades of persistence from patients, families, advocates, researchers, and clinicians who refused to accept that progress was out of reach.

Daraxonrasib has transformed the conversation, and this is only the beginning.

We are entering the era of RAS-targeted therapy, with combinations, earlier-line treatment, and next-generation approaches already advancing.

Today was historic.
The best is yet to come. #ASCO26 #PancreaticCancer #Daraxonrasib #CancerResearch
@letswinpc @RevMedicines

[PanCAN @PanCAN]

In this episode of PancChat, host @AlisynCamerota speaks with Elliot Fishman, MD about the promise of artificial intelligence in the early detection of #pancreaticcancer. 🔎

Dr. Fishman explains how AI-powered imaging tools are being trained to identify tumors as small as two centimeters and why that breakthrough could help save tens of thousands of lives each year. He also discusses the FELIX 2.0 project, the challenges of implementing AI across health systems and how AI is already advancing cancer care beyond pancreatic cancer — from mammography to drug discovery.

Listen to the PancChat podcast at 🔗 https://t.co/zIzFgM1xUz.

PancChat is a collaboration between @LetsWinPC and PanCAN. 💜

[Elvina Almuradova @Dr_ElvinaA]

RASolute-302 may carry a RAS name, but its impact extends far beyond RAS biology.

Nearly doubling OS in metastatic pancreatic cancer (13.2 vs 6.6 months; HR 0.40) is an achievement that truly captured attention at #ASCO26.

In a disease with so few victories, daraxonrasib looks every bit like a future standard of care. @Larvol @OncoAlert @OncoInsights #asco26

[Dr. Allyson Ocean @drallysonocean]

What an amazing #ASCO26 with our awesome @WCMGIcancer team! @weillcornell @nyphospital @letswinpc @ASCO

[lvisa @oncolvisa]

Historic moment in pancreatic cancer.
RASolute 302 is practice-changing. Now we need fast regulatory approval and patient access in Europe, Spain and Catalonia. @hospitaldelmar @PNavarro_Lab @SCPancrees @letswinpc @ACanPan #ASCO26 #PancreaticCancer#SEOM

[ASCO @ASCO]

Major news from #ASCO26: A multi-selective RAS(ON) inhibitor nearly doubles survival time in people with metastatic pancreatic cancer. “This is absolutely practice-changing” says @ShrutiPatelMD in this Science in Seconds. #pancan

Read the abstract: https://t.co/MbVCqGvYfz

[Yüksel Ürün @DrYukselUrun]

This is not simply a new pancreatic cancer drug.

It is a reminder that even “undruggable” biology can become treatable with persistence.

Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists